 - Rapidly progressive disease in major organs i.e. lymphangitic spread, bulky liver metastasis or known brainleptomeningeal metastatic disease requiring active therapy; patients with asymptomatic, stable previously treated metastases to the central nervous system and surrounding tissues are eligible; however patients must not have a requirement for corticosteroids due to central nervous system metastases at the time of study entry 